Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.

Trial Profile

A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Fracture
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2018 According to a Bone Therapeutics media release, the company expects to submit the Clinical Trial Application (CTA) for the trial in second half of 2019.
    • 24 Jan 2018 New trial record
    • 23 Jan 2018 According to a Bone Therapeutics media release, preparation has been initiated and the start of the study is anticipated in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top